Leukemia

Article	Citations
FBXO21 mediated degradation of p85α regulates proliferation and survival of acute myeloid leukemia	1976
A prognostic survival nomogram for persons with extra-nodal natural killer-/T-cell lymphoma	1719
The evolution of preclinical models for myelodysplastic neoplasms	169
Enhanced Risk Stratification for Children and Young Adults with B-Cell Acute Lymphoblastic Leukemia: A Children’s Oncology Group Report	159
Response to: Ruxolitinib withdrawal due to the COVID-19	148
Does older age justify chlorambucil control arms for chronic lymphocytic leukemia clinical trials: a SEER-Medicare analysis	126
Retraction Note: SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide	125
Hal E. Broxmeyer PhD: Experimental haematologist and umbilical cord blood cell transplant pioneer (27 November, 1944–8 December, 2021)	116
Clonal hematopoiesis and its impact on the aging osteo-hematopoietic niche	116
Emil J. Freireich: Legend in Cancer Research (March 16, 1927 to February 1, 2021)	106
Single-cell analysis reveals the chemotherapy-induced cellular reprogramming and novel therapeutic targets in relapsed/refractory acute myeloid leukemia	104
Identification of therapeutic targets of the hijacked super-enhancer complex in EVI1-rearranged leukemia	103
DELE1 haploinsufficiency causes resistance to mitochondrial stress-induced apoptosis in monosomy 5/del(5q) AML	95
PDP1 is a key metabolic gatekeeper and modulator of drug resistance in FLT3-ITD-positive acute myeloid leukemia	88
Changing causes of death in persons with haematological cancers 1975–2016	86
Significance of chromosome 2p gain in ibrutinib-treated chronic lymphocytic leukemia patients	82
MCL1 as a therapeutic vulnerability in Burkitt lymphoma	80
Daniel Catovsky (1937–2022)	73
Novel causative variants of VEXAS in UBA1 detected through whole genome transcriptome sequencing in a large cohort of hematological malignancies	72
Prevalence of UBA1 mutations in MDS/CMML patients with systemic inflammatory and auto-immune disease	70
Phase 2 study using low dose cytarabine for adult patients with newly diagnosed Langerhans cell histiocytosis	68
Tumor heterogeneity and immune-evasive T follicular cell lymphoma phenotypes at single-cell resolution	67
Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial	67
Potential and pitfalls of whole transcriptome-based immunogenetic marker identification in acute lymphoblastic leukemia; a EuroMRD and EuroClonality-NGS Working Group study	64
Role of MBD3-SOX2 axis in residual myeloma following pomalidomide	64

External validation of the predictive scoring systems for molecular responses in chronic myeloid leukaemia receiving initial imatinib-therapy	63
Analysis of autophagy in DLBCL reveals subtype-specific differences and the preferential targeting of ULK1 inhibition in GCB-DLBCL provides a rationale as a new therapeutic approach	63
Functional precision oncology for follicular lymphoma with patient-derived xenograft in avian embryos	62
Mutant IL7R collaborates with MYC to induce T-cell acute lymphoblastic leukemia	61
Combination p53 activation and BCL-xL/BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia	61
ACOX1-mediated peroxisomal fatty acid oxidation contributes to metabolic reprogramming and survival in chronic lymphocytic leukemia	61
Context-dependent role of trisomy 6 in myelodysplastic neoplasms and acute myeloid leukemia: a multi-omics analysis	60
The P2X4 purinergic receptor has emerged as a potent regulator of hematopoietic stem/progenitor cell mobilization and homing—a novel view of P2X4 and P2X7 receptor interaction in orchestrating stem ce	60
Physician and patient perceptions on randomization of treatment intensity for unfit adults with acute myeloid leukemia and other high-grade myeloid neoplasm	59
The potential of cell-free DNA to reveal the molecular profiles of Langerhans cell histiocytosis and Erdheim–Chester disease in adults	57
What role for somatic mutations in systemic inflammatory and autoimmune diseases associated with myelodysplastic neoplasms and chronic myelomonocytic leukemias?	56
Immunoglobulin superfamily member 8 maintains myeloid leukemia stem cells through inhibition of β-catenin degradation	55
Early relapse is an adverse prognostic marker in systemic immunoglobulin light chain (AL) Amyloidosis	55
Real-world analysis of teclistamab in 123 RRMM patients from Germany	55
A senescence stress secretome is a hallmark of therapy-related myeloid neoplasm stromal tissue occurring soon after cytotoxic exposure	55
PU.1 and MYC transcriptional network defines synergistic drug responses to KIT and LSD1 inhibition in acute myeloid leukemia	55
Small-molecule inhibitor targeting the Hsp70-Bim protein–protein interaction in CML cells overcomes BCR-ABL-independent TKI resistance	55
A key role of the WEE1-CDK1 axis in mediating TKI-therapy resistance in FLT3-ITD positive acute myeloid leukemia patients	54
COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey	53
ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation?	53
Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures	53
Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the DRST and GREM registries	52
REXO5 promotes genomic integrity through regulating R-loop using its exonuclease activity	51
RUNX1 mutations mitigate quiescence to promote transformation of hematopoietic progenitors in Fanconi anemia	51
Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community	51
Evolution of T-cell fitness through AML progression: enhanced bispecific T-cell engager-mediated function of bone marrow T cells at remission compared to initial diagnosis and relapse	51
Panel-based RNA fusion sequencing improves diagnostics of pediatric acute myeloid leukemia	50
Single base substitution and insertion/deletion mutational signatures in adult core binding factor acute myeloid leukemia	50
Quantifying measurable residual disease correctly	50
Classification of rare pediatric myeloid neoplasia—Quo vadis?	48
Genome-wide trans-ethnic meta-analysis identifies novel susceptibility loci for childhood acute lymphoblastic leukemia	48
Clonal hematopoiesis is associated with hematological toxicity during lenalidomide-based therapy for MCL	48
Splenomegaly (SPML) in polycythemia vera (PV): its clinical significance and its relation to symptoms, post-polycythemic myelofibrosis (PPMF) and survival	47
IL-10R inhibition reprograms tumor-associated macrophages and reverses drug resistance in multiple myeloma	46
Cohesin mutations in acute myeloid leukemia	46
Fc-fused IL-7 mobilizes long-term HSCs in a pro-B cell-dependent manner and synergizes with G-CSF and AMD3100	46
Neoantigen reactive T cells correlate with the low mutational burden in hematological malignancies	46
Inhibition of NOTCH4 sensitizes FLT3/ITD acute myeloid leukemia cells to FLT3 tyrosine kinase inhibition	44
Recommendations from the AML molecular MRD expert advisory board	44
Nucleic acid therapeutics as differentiation agents for myeloid leukemias	43
Effect of ECOG performance status on outcomes in patients with acute myeloid leukemia and other high-grade myeloid neoplasms	43
Comparison of the revised 4th (2016) and 5th (2022) editions of the World Health Organization classification of myelodysplastic neoplasms	43
CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results	42
An “off-the-shelf” CD2 universal CAR-T therapy for T-cell malignancies	42
SF3B1 mutations in AML are strongly associated with MECOM rearrangements and may be indicative of an MDS pre-phase	41
In vivo kinetics of early, non-random methylome and transcriptome changes induced by DNA-hypomethylating treatment in primary AML blasts	41
Hairy cell leukemia variant and WHO classification correspondence Re: 5th edition WHO classification haematolymphoid tumors: lymphoid neoplasms	41
Germline CHEK2 mutations in patients with myeloid neoplasms	40
Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR—final report from AFTER-SKI	40
Siglec-6 is a target for chimeric antigen receptor T-cell treatment of chronic lymphocytic leukemia	40

Perspectives on acute myeloid leukemia diagnosis: a comparative analysis of the latest World Health Organization and the International Consensus Classifications	39
Kinase-independent role of mTOR and on-/off-target effects of an mTOR kinase inhibitor	38
The complex karyotype in hematological malignancies: a comprehensive overview by the Francophone Group of Hematological Cytogenetics (GFCH)	38
Treatment and survival for patients with localized primary ocular adnexal extranodal marginal zone lymphoma	38
Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia	37
Improved survival in multiple myeloma during the 2005–2009 and 2010–2014 periods	37
Targeting the NOTCH1-MYC-CD44 axis in leukemia-initiating cells in T-ALL	37
Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG)	37
Chronic lymphocytic leukemia patient-derived xenografts recapitulate clonal evolution to Richter transformation	36
OST-01, a natural product from Baccharis coridifolia, targets c-Myc-dependent ribogenesis in acute myeloid leukemia	36
Inability to phosphorylate Y88 of p27Kip1 enforces reduced p27 protein levels and accelerates leukemia progression	36
Differences in classification schemata for myelodysplastic/myeloproliferative overlap neoplasms	36
Inserting EF1α-driven CD7-specific CAR at CD7 locus reduces fratricide and enhances tumor rejection	36
Mutations in DEAD/H-box helicase 11 correlate with increased relapse risk in adults with acute myeloid leukaemia with normal cytogenetics	36
Genomic and evolutionary portraits of disease relapse in acute myeloid leukemia	36
CD7 targeted “off-the-shelf” CAR-T demonstrates robust in vivo expansion and high efficacy in the treatment of patients with relapsed and refractory T cell malignancies	35
The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial	35
Myelodysplastic neoplasm-associated U2AF1 mutations induce host defense defects by compromising neutrophil chemotaxis	35
A unique role of p53 haploinsufficiency or loss in the development of acute myeloid leukemia with FLT3-ITD mutation	35
Differential prognostic impact of IDH1 and IDH2 mutations in chronic myelomonocytic leukemia	34
BCR::ABL1 Proteolysis-targeting chimeras (PROTACs): The new frontier in the treatment of Ph+ leukemias?	34
Genome-wide DNA methylation-analysis of blastic plasmacytoid dendritic cell neoplasm identifies distinct molecular features	34
DNA-TG and risk of sinusoidal obstruction syndrome in childhood acute lymphoblastic leukemia	34
“Blasts” in myeloid neoplasms – how do we define blasts and how do we incorporate them into diagnostic schema moving forward?	33
Comparison between measurable residual disease relapse and morphologic relapse in acute myeloid leukemia and high-grade myeloid neoplasms	33
SF3B1 mutated MDS: Blast count, genetic co-abnormalities and their impact on classification and prognosis	33
Why are haematopoietic stem cells in the bone marrow: ontology recapitulates phylogeny	33
The IL-3, IL-5, and GM-CSF common receptor beta chain mediates oncogenic activity of FLT3-ITD-positive AML	33
Hematopoiesis and innate immunity: an inseparable couple for good and bad times, bound together by an hormetic relationship	32
Nuclear war and physicians’ social responsibility	32
The 5th edition of the WHO classification of haematolymphoid tumors: comments from the Groupe Francophone de Cytogénétique Hématologique (GFCH)	32
Somatic TP53 single nucleotide variants, indels and copy number alterations in chronic myelomonocytic leukemia (CMML)	31
DDX41 coordinates RNA splicing and transcriptional elongation to prevent DNA replication stress in hematopoietic cells	31
Interleukin-10 suppression enhances T-cell antitumor immunity and responses to checkpoint blockade in chronic lymphocytic leukemia	31
Co-targeting of the thymic stromal lymphopoietin receptor to decrease immunotherapeutic resistance in CRLF2-rearranged Ph-like and Down syndrome acute lymphoblastic leukemia	31
Exploiting the fibroblast growth factor receptor-1 vulnerability to therapeutically restrict the MYC-EZH2-CDKN1C axis-driven proliferation in Mantle cell lymphoma	31
Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia	31
Pediatric T-ALL type-1 and type-2 relapses develop along distinct pathways of clonal evolution	31
Multi-hit TET2 mutations as a differential molecular signature of oligomonocytic and overt chronic myelomonocytic leukemia	31
KDM6 demethylases integrate DNA repair gene regulation and loss of KDM6A sensitizes human acute myeloid leukemia to PARP and BCL2 inhibition	31
Venetoclax consolidation in high-risk CLL treated with ibrutinib for ≥1 year achieves a high rate of undetectable MRD	31
The landscape of RNA-chromatin interaction reveals small non-coding RNAs as essential mediators of leukemia maintenance	30
Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohorts	30
Point-of-care BCR::ABL1 transcript monitoring using capillary dried blood in chronic myeloid leukemia patients	30
Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patients	30
COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia	29
A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML	29
Characterization of leukemia progression in the Cbfb-MYH11 knockin mice by single cell RNA sequencing	29
Osteocyte-derived exosomes confer multiple myeloma resistance to chemotherapy through acquisition of cancer stem cell-like features	29
Measurable residual disease in haematological and solid cancers	29
Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma	28
Modeling clonal hematopoiesis in umbilical cord blood cells by CRISPR/Cas9	28
Association of hematologic response and assay sensitivity on the prognostic impact of measurable residual disease in acute myeloid leukemia: a systematic review and meta-analysis	28
Combining LSD1 and JAK-STAT inhibition targets Down syndrome-associated myeloid leukemia at its core	28
High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance	28
Increasing recognition and emerging therapies argue for dedicated clinical trials in chronic myelomonocytic leukemia	28
Targeting a mitochondrial E3 ubiquitin ligase complex to overcome AML cell-intrinsic Venetoclax resistance	27
Genomic abnormalities of TP53 define distinct risk groups of paediatric B-cell non-Hodgkin lymphoma	27
Co-targeting leukemia-initiating cells and leukemia bulk leads to disease eradication	27
Circulating cytokines present in multiple myeloma patients inhibit the osteoblastic differentiation of adipose stem cells	27
Who wins the combat, CAR or TCR?	27
Genomic DNA-based measurable residual disease monitoring in pediatric acute myeloid leukemia: unselected consecutive cohort study	27
Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients	27
Are measurable residual disease results after consolidation therapy useful in children with acute lymphoblastic leukemia?	26
The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma—a randomized, open-label phase III trial of the European mantle cell lymp	26
Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis	26
What is the impact of failing to achieve TKI therapy milestones in chronic myeloid leukemia	26
Phase 3 study of gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia	26
A phase II trial of ipilimumab, nivolumab, or ipilimumab and nivolumab with or without azacitidine in relapsed or refractory myelodysplastic neoplasms	26
Genome-wide CRISPR/Cas9 library screening identified OGDH as a regulator of disease progress and resistance to decitabine in myelodysplastic neoplasm by reprogramming glutamine metabolism	25
Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome	25
Diverse mechanisms of leukemogenesis associated with PAX5 germline mutation	25
Genetic and transcriptomic analyses of diffuse large B-cell lymphoma patients with poor outcomes within two years of diagnosis	25
3-Ketodihydrosphingosine reductase maintains ER homeostasis and unfolded protein response in leukemia	25
Invasive fungal diseases impact on outcome of childhood ALL – an analysis of the international trial AIEOP-BFM ALL 2009	24
Dual inhibition of CHK1/FLT3 enhances cytotoxicity and overcomes adaptive and acquired resistance in FLT3-ITD acute myeloid leukemia	24
Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis	24
Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/F	24
Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial	24
Analysis and therapeutic targeting of the EP300 and CREBBP acetyltransferases in anaplastic large cell lymphoma and Hodgkin lymphoma	24

Clonal medicine targeting DNA damage response eradicates leukemia	24
Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial	24
MCL1 regulates AML cells metabolism via direct interaction with HK2. Metabolic signature at onset predicts overall survival in AMLs’ patients	24
Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma	24
Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9	24
Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial	24
Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation	24
Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update	23
Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study	23
Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: reevaluation of the defining characteristics in a registry-based cohort	23
The KMT2A recombinome of acute leukemias in 2023	22
Space exploration and cancer: the risks of deeper space adventures	22
Deep learning detects acute myeloid leukemia and predicts NPM1 mutation status from bone marrow smears	22
Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML	22
mTOR inhibition amplifies the anti-lymphoma effect of PI3Kβ/δ blockage in diffuse large B-cell lymphoma	22
UBTF tandem duplications define a distinct subtype of adult de novo acute myeloid leukemia	22
Focal disruption of DNA methylation dynamics at enhancers in IDH-mutant AML cells	22
Inflammation and infection in plasma cell disorders: how pathogens shape the fate of patients	22
Nucleolin as activator of TCF7L2 in human hematopoietic stem/progenitor cells	22
JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis	22
Catch me if you can: how AML and its niche escape immunotherapy	22
Targeting CERS6-AS1/FGFR1 axis as synthetic vulnerability to constrain stromal cells supported proliferation in Mantle cell lymphoma	21
Correction: Translatome proteomics identifies autophagy as a resistance mechanism to on-target FLT3 inhibitors in acute myeloid leukemia	21
Correction: Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer	21
A comparison of the International Consensus and 5th World Health Organization classifications of mature B-cell lymphomas	21
Real life evaluation of AlphaMissense predictions in hematological malignancies	21
Correction to: Functional classification of RUNX1 variants in familial platelet disorder with associated myeloid malignancies	21
Correction to: Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation	21
Correction: Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib – interim results from the DAstop2 trial	21
Culture expansion of CAR T cells results in aberrant DNA methylation that is associated with adverse clinical outcome	21
MiRNA-363-3p/DUSP10/JNK axis mediates chemoresistance by enhancing DNA damage repair in diffuse large B-cell lymphoma	21
Publisher Correction: Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age	21
Publisher Correction: SIRT7: an influence factor in healthy aging and the development of age-dependent myeloid stem-cell disorders	21
Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study	21
A simple algorithm with one flow cytometric MRD measurement identifies more than 40% of children with ALL who can be cured with low-intensity therapy. The ALL-MB 2008 trial results	21
T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments	21
Correction: Continuous Indexing of Fibrosis (CIF): improving the assessment and classification of MPN patients	21
Correction: complex landscape of alternative splicing in myeloid neoplasms	20
Dimethyl fumarate ameliorates chronic graft-versus-host disease by inhibiting Tfh differentiation via Nrf2	20
Characterisation and prognostic impact Of ZRSR2 mutations in myeloid neoplasms	20
Can PROTACs cure Leukemia?	20
Correction: Mutant SETBP1 enhances NRAS-driven MAPK pathway activation to promote aggressive leukemia	20
Dimethyl fumarate and extracorporeal photopheresis combination-therapy synergize in inducing specific cell death and long-term remission in cutaneous T cell lymphoma	20
Essential role of Dhx16-mediated ribosome assembly in maintenance of hematopoietic stem cells	20
Characterization of myeloproliferative neoplasms based on genetics only and prognostication of transformation to blast phase	20
Correction: Generation and characterization of a novel hematopoietic progenitor cell line with DC differentiation potential	20
Correction to: Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113AML patients	20
Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study	20
Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD, nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic leukemia and lymphoma	20
Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial	20
Correction: Genomic analysis of cellular hierarchy in acute myeloid leukemia using ultrasensitive LC-FACSeq	19
Liquid biopsy: an evolving paradigm for the biological characterisation of plasma cell disorders	19
Publisher Correction: Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide—an International Collaborative Study	19
A DNA methylation database of human and mouse hematological malignancy cell lines	19
Correction: Frequent HLA-DR loss on hematopoietic stem progenitor cells in patients with cyclosporine-dependent aplastic anemia carrying HLA-DR15	19
An MDM2 degrader for treatment of acute leukemias	19
A positive feedback loop regulation between NOTCH1 and USP11 in T-cell leukemia	19
Rheumatoid arthritis and the risk of hematologic malignancies: a nationwide cohort study	19
Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes	19
Correction to: TAL1 hijacks MYCN enhancer that induces MYCN expression and dependence on mevalonate pathway in T-cell acute lymphoblastic leukemia	19
The epigenetic state of the cell of origin defines mechanisms of leukemogenesis	18
MSI2 mediates WNT/β-Catenin pathway function in hematopoietic stem cells	18
Venetoclax in combination with hypomethylating agents in chronic myelomonocytic leukemia: a propensity score matched multicenter cohort study	18
The landscape of small nucleolar RNA expression in multiple myeloma is determined by cytogenetic alterations	18
STING is crucial for the survival of RUNX1::RUNX1T1 leukemia cells	18
Comparative small molecule screening of primary human acute leukemias, engineered human leukemia and leukemia cell lines	18
Genome-wide CRISPR screen identifies MAD2L1BP and ANAPC15 as targets for brentuximab vedotin sensitivity in CD30+ peripheral T-cell lymphoma	18
Antibody blockade of the PSGL-1 immune checkpoint enhances T-cell responses to B-cell lymphoma	18
Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial	18
Prof. Anton Hagenbeek 1948–2021: Father of MRD and Lymphoma Expert	18
Significance of hereditary gene alterations for the pathogenesis of adult bone marrow failure versus myeloid neoplasia	18
CD36 cell surface expression as a surrogate marker to identify ABL/JAK-class kinase fusions in pediatric BCP-ALL	18
Anagrelide and idarubicin combination induces GSDME-mediated pyroptosis as a potential therapy for high-PDE3A acute myeloid leukemia	18
Adding eltrombopag to intensive immunosuppressive therapy for severe aplastic anaemia may help adult patients achieve outcomes similar to paediatric patients	18
Multi-omic analysis of chronic myelomonocytic leukemia monocytes reveals metabolic and immune dysregulation leading to altered macrophage polarization	18
Loss of Dnajc21 leads to cytopenia and altered nucleotide metabolism in zebrafish	18
TLE4 is a repressor of the oncogenic activity of TLX3 in T-cell acute lymphoblastic leukemia	18
POEMS syndrome remains a mystery after 40 years	17
Risk prediction in MDS: independent validation of the IPSS-M—ready for routine?	17
Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial	17
Aberrant activation of TRIP13-EZH2 signaling axis promotes stemness and therapy resistance in multiple myeloma	17
Combination of chemotherapy and all-trans retinoic acid for the treatment KMT2A-rearranged infant acute lymphoblastic leukemia. Results of the MLL-Baby trial	17
Comprehensive response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: a proposal from the MLN International Working Group	17
Transient regulatory T-cell targeting triggers immune control of multiple myeloma and prevents disease progression	17
Evidence supporting that the attribution of first success in use of arsenic for the treatment of leukaemia should be to David Lissauer (1836–1892)	17
Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia	17
Improving prognostic assignment in older adults with multiple myeloma using acquired genetic features, clonal hemopoiesis and telomere length	17
RNA-sequencing data-driven dissection of human plasma cell differentiation reveals new potential transcription regulators	17
Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA	17
Impaired binding affinity of YTHDC1 with METTL3/METTL14 results in R-loop accumulation in myelodysplastic neoplasms with DDX41 mutation	17
Acquired somatic variants in inherited myeloid malignancies	16
Integrated proteogenomic analysis for inherited bone marrow failure syndrome	16
Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study	16
Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma	16
Transient regulation of RNA methylation in human hematopoietic stem cells promotes their homing and engraftment	16